Kornimate/medical-research-clean huggingface dataset:
study of cytokines in children with opsoclonus-myoclonus syndrome

Conditions: Opsoclonus-myoclonus Syndrome

Summary: the purpose of this study is to determine if cytokines, inflammatory mediators, are increased in spinal fluid and blood, correlate with disease activity, and could serve as biomarkers or therapeutic targets in children with opsoclonus-myoclonus syndrome (oms), an autoimmune complication of the tumor neuroblastoma.

in this translational research, immunological mechanisms that underlie the assault of the immune system on the brain in paraneoplastic opsoclonus-myoclonus syndrome (oms) are under evaluation. to test our principal hypothesis that there is an imbalance of pro-inflammatory (th1) and anti-inflammatory (th2) cytokines in oms, a comprehensive cytokine panel will be measured by enzyme-linked immunosorbent assay (elisa) and multiplexed fluorescent bead-based immunoassay detection (luminex 100 lab map system)in blood and cerebrospinal fluid (csf) of 400 children. to test the second hypothesis that cytokines could serve as biomarkers of disease activity in oms, cytokine concentrations will be correlated with clinical variables, such as disease severity, oms duration, prior relapses, and remissions, as well as immunological variables, such as lymphocyte subset analysis. the cytokine 'biomarker profile' could aid decision making for early intervention by identifying children at high risk for relapse and poor outcome and allow targeting of the most implicated inflammatory cytokines by cytokine therapies. to test our third hypothesis that lack of response to immunotherapy is due in part to failure to increase the expression of anti-inflammatory th2 cytokines, we will make paired pre/post comparisons of the impact of immunotherapies given in the course of clinical care \[steroids, adrenocorticotropin (acth), intravenous immunoglobulins (ivig), rituximab, chemotherapy, other drugs, combinations\] on the cytokine and clinical profile. this research could lead to the application of commercially-available cytokines and cytokine blockers or to the development of new ones for oms.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of oms exclusion criteria: * equivocal diagnosis * contraindications to lumbar puncture * treatment with agents outside the scope of the study

Keywords: paraneoplastic neuroblastoma kinsbourne syndrome autoimmune disease immunotherapy ataxia
supportive wheelchair back compared to fabric back

Conditions: Spinal Cord Injuries

Summary: this study tests using a wheelchair back that supports the spine in a neutral position and one that allows the spine and pelvis to fall into a posterior pelvic tilt.

individuals will randomly start with the supportive back vs the unsupportive back. measurements of the spine and pelvis will be taken. forward upward reach, one stroke push, times forward push and ramp skills will be assessed.

Eligibility criteria:
inclusion criteria: * complete spinal cord injury with levels * full time wheelchair users * english speaking in order to understand the consent exclusion criteria: * over 250 pounds in body weight * inability to grip a wheelchair push rim * individual with pressure ulcer * individual with shoulder pain
treatment of patients with major depressive disorder with mk0869 (0869-060)(completed)

Conditions: Major Depressive Disorder

Summary: a clinical study to determine the efficacy and safety of an investigational medication (mk0869) in the treatment of depression.

the duration of treatment is 8 weeks.

Eligibility criteria:
patients with major depressive disorder
paternal involvement in breastfeeding

Conditions: Breastfeeding; Paternal Behavior; Depression

Summary: paternal involvement in breastfeeding has been identified as a significant predictor in maternal breastfeeding outcomes. the main aim of this study is to examine the relationship between reported paternal breastfeeding support and paternal-infant attachment with exclusive breastfeeding and total breastfeeding duration. the hypothesis is that paternal involvement in breastfeeding increase exclusive breastfeeding rates, total breastfeeding duration and strengthen paternal-infant attachment.

initiation, duration and exclusivity of breastfeeding are greatly influenced by paternal involvement in breastfeeding. previous studies showed that fathers who are involved in the breastfeeding process have stronger attachments with their babies. however, research on fathers' involvement in their partners' breastfeeding is lacking and there are no comprehensive studies conducted on the effects of the paternal involvement and infant attachment on exclusive breastfeeding (eb) and total breastfeeding duration. therefore, the aim of the study is to examine the relationship between fathers reported breastfeeding support and paternal-infant attachment with exclusive breastfeeding and total breastfeeding duration. data will be collected from a tertiary university hospital. the study will be conducted in two phases. in the first phase, the researcher will approach healthy, term, one month old babies and their fathers who fulfilled the eligibility criteria and will invite them to participate in the study. informed consent will be obtained from participating fathers. the partner breastfeeding influence scale will be used to measure fathers' involvement in their partner's breastfeeding, paternal-infant attachment, paternal depression, and marital adjustment will be measured with paternal-infant attachment questionnaire, edinburgh postpartum depression scale and marital adjustment scale respectively. four sets of questionnaires will be administered at two time points for the study. the first set will be administered at postpartum first month. the second set of data will be collected at postpartum six months. in the second phase, fathers participating in the study will be interviewed for breastfeeding duration and factors associated with cessation will be explored at postpartum 12 and 24 months.

Eligibility criteria:
inclusion criteria: fathers of * one-month-old, * healthy, * breastfed infants exclusion criteria: * infants with a birth weight less than 2500 grams * infants who are less than 37 weeks gestation * infants with prenatally suspected or diagnosed congenital defects * parents with major depression * divorced or separated couples

Keywords: depression breastfeeding paternal depression paternal involvement marital relationship
barusiban subcutaneously for reducing implantation failure due to uterine contractions

Conditions: Infertility

Summary: this trial investigates the effects of fe 200440 compared to placebo on implantation rate in women undergoing ivf/icsi treatment


Eligibility criteria:
inclusion criteria: * women aged 18-37 years * women who have undergone 2-4 previous fresh in vitro fertilization (ivf) or intracytoplasmatic sperm injection (icsi) cycles that all resulted in a negative βhcg test, despite transfer of at least one embryo/blastocyst of good quality * women who have in the current controlled ovarian stimulation cycle for ivf/icsi followed the long gonadotrophin releasing hormone (gnrh) agonist or gnrh antagonist protocol, received hcg for triggering of final follicular maturation and have undergone oocyte retrieval for ivf/icsi with the purpose of fresh transfer * retrieval of at least 6 oocytes in the current controlled ovarian stimulation cycle * subjects should have at least one embryo of good quality available for transfer on day 3, or at least one good quality blastocyst available for transfer on day 5 exclusion criteria: * a total of 6 or more controlled ovarian stimulation cycles for ivf/icsi * abnormal karyotype * uterine pathology or hydrosalpinx * diagnosed with acquired or congenital thrombophilia disease
research on the complex scientific mechanisms underlying exercise and health: construction and application of a mechanistic model and public database（ciss）

Conditions: Type 2 Diabetes Mellitus With Dawn Phenomena

Summary: dear sugar lovers: greetings! in order to improve the knowledge of chronic disease prevention and control of sugar users and promote health, the investigators plan to organise participants to participate in the diabetes exercise intervention, science promotion and publicity of chronic disease prevention and control knowledge survey, and the investigators hope to get participant's support and cooperation. please read the following procedure carefully: 1. exercise intervention: we 2023 late november to start the intervention course. 2. blood test 2 times (fasting insulin, glycated haemoglobin, total cholesterol, triglyceride, hdl, ldl, fasting blood glucose, tumour necrosis factor, etc., finger blood glucose. all the above tests are free of charge 3. popularisation: we will join hands with the community health service centre of liaojin village to conduct at least 3 talks on the prevention and control of diabetes. the investigators will cooperate with the community health service centre of lijincun to carry out at least 3 times of knowledge dissemination on diabetes prevention and control. 4. chronic disease knowledge prevention and control survey: for your physical and mental health development, the follow-up questionnaire is a knowledge survey questionnaire. please read the questions carefully. participants privacy and confidentiality will be strictly protected and will not be disclosed to any unauthorised person. if participants agree to participate in the programme, please confirm the following information and sign! 1. co-operation and co-ordination: the investigators promise to participate in the whole project and maintain good communication and co-operation. the investigators will keep abreast of and respond to notices, feedback and suggestions, and provide the necessary support and co-operation. 2. informed consent: the investigators understand and agree to participate in the project.


Eligibility criteria:
inclusion criteria: * patients with t2dm and diagnosed 6 months or more ago * meet the criteria of the dawn phenomenon * willing to sign the informed consent form * voluntarily accept the relevant examinations and tests * no change in sleep habits in the past 2 weeks exclusion criteria: * t1dm, special type of diabetes, secondary diabetes, gestational diabetes; * nocturnal hypoglycemic reactions due to oral hypoglycemic agents or insulin use * patients with serious complications
nbf gingival gel application after impacted lower third molar surgery

Conditions: Alveolar Osteitis

Summary: background: alveolar osteitis is one of the most frequent complications after lower third molar extraction, and is usually accompanied by inflammation, pain and poor wound healing. several local interventions have been used to reduce these complications with limited effectiveness. purpose: to clinically evaluate the use of propolis extract, nanovitamin c and nanovitamin e gel for the prevention of surgical complications related to impacted lower third molar extraction. methods: a randomized, triple-blind, split-mouth, pilot study is being performed in patients needing bilateral lower third molar extraction with similar surgical difficulty. surgical extractions are randomly being performed and nbf gingival gel (tg) or placebo (pbg) are randomly being applied inside postextraction sockets by a blinded surgeon. the patients are being instructed to apply it 3 times/day in the surgical wound for 7 days. one month later, the contralateral wisdom tooth is being extracted and the opposite gel is being applied. alveolar osteitis (ao) is being diagnosed following blum's criteria. swelling is being assessed by measuring the facial perimeter. wound healing is being evaluated with a semi-quantitative scale as good, satisfactory or insufficient. postoperative pain is being recorded using a visual analog scale (vas) for 7 days. analgesic pill intake is being recorded by each patient. variables are being registered by a blinded researcher to 3m extractions at one, two, three and seven postoperative days.


Eligibility criteria:
inclusion criteria: the inclusion criteria are: * cooperative adult patients able to fulfil the study protocol, * needing surgical extractions of both lower third molars, * with similar surgical difficulty according to pederson scale. exclusion criteria: the exclusion criteria are * refuse to participate in the study, * failure to attend 24, 48, and 72 hours, as well as, 7 days post-surgical appointment visits, * smokers, * systemic diseases as diabetes mellitus or being immunosuppressed, * patients who take local or systemic antibiotics less than 3 months ago, anti-inflammatory or anticoagulant medication in the previous 4 weeks, * patients who require antibiotic prophylaxis, * pregnant or breastfeeding women, * patients with chronic periodontitis in active phase or * with history of allergies to any of the components of local anaesthetics, antibiotics, aines, or nbf gingival gel.

Keywords: third molar surgery oral surgery propolis nbf gingival gel post-surgical complications clinica trial
reinforcement of the impact of a functional insulin therapy training course by telemonotoring with a pda-phone in type 1 diabetic patients. the telfit study patients

Conditions: Type 1 Diabetes Mellitus

Summary: telfit is a monocenter, controlled, randomised trial. it focuses on type 1 diabetes patients that have attended a functional insulin therapy training course. the primary objective of the telfit study is to evaluate whether a pda with telemonitoring by phone reinforces the effects of the functional insulin therapy training course as compared with conventional care. main judgment criteria: comparison of hba1c means between m0 (start) and m3(3 months)

all patients will attend a functional insulin therapy training course and be randomized into 2 groups. one group will receive a pda-phone and one month of phone consultations with a nurse and a physician. the other group will only have the usual paper support. this study compares the evolution of hba1c in the 2 groups over a period of 3 months. it also assesses time spent by nurses and physicians, changes in quality of life, hypoglycaemia frequency and weight changes.

Eligibility criteria:
inclusion criteria: * type 1 diabetes mellitus for ≥ 6 months or more * age \> 18 year old * the patient has attended a functional insulin therapy class or workshop * insulin basal-bolus therapy for at least 6 months. at inclusion, patients should be treated either with a long-acting insulin and insulin rapid analog before each meal, or with rapid insulin analog delivered with a pump * ability to understand how the pda-phone works and ability to use it * social security membership or benefit from social security * patients equipped with a memory blood glucose monitor * informed consent, with a signed and approved form exclusion criteria: * underage patient, major patient under guardianship or protected by the law * patient with any unstable associated evolutive pathology that could cause a diabetes imbalance within the coming year * change in diabetes treatment within the 3 months before inclusion or planned during the study * patient who needs a more frequent diabetic follow-up than in the protocol (especially severe or evolving complication due to diabetes) * patient attending another education program within the 3 months before inclusion or planning to attend one during the study * patient with toxicomania, alcoholism or psychological troubles that could impact the study * type-2-diabetic patient * patient who doesn't need strict metabolic objectives * pregnant or possibly pregnant woman * person with no freedom (prisoner)

Keywords: type 1 diabetes pda phone (personal digital assistant) hba1c
analgesic efficacy of high frequency spinal cord stimulation

Conditions: Lowback and Leg Pain

Summary: the aim of the study is to compare the efficacy of high frequency (hf scs) stimulation and sham stimulation (sham scs - i.e. no stimulation) and conventional spinal cord stimulation (conv scs) on the patient reported global impression of change, pain intensity and health related quality of life.


Eligibility criteria:
inclusion criteria: * signed informed consent * treated with spinal cord stimulation * stable pain relief achieved exclusion criteria: * failure to give informed consent * unable to use or understand how to handle the equipment, pgic,vas score or eq-5d questionnaires.
dexamethasone & bupivacaine vs bupivacaine alone in combined femoral and sciatic nerve block for perioperative analgesia in patients undergoing lower limb surgeries

Conditions: Pain

Summary: in regional anesthesia local anaesthetics alone provide analgesia for not more than 4-8 hours. increasing the duration of local anaesthetic action is often desirable because it prolongs surgical anaesthesia and analgesia. different additives have been used to prolong regional blockade. vasoconstrictors can be used to constrict vessels, thereby reducing vascular absorption of the local anaesthetic. additives like opioids, clonidine and verapamil were added to local anaesthetics, but the results are either inconclusive or associated with side effects. steroids when used intrathecally are reported to cause arachnoiditis, but there is no evidence suggesting any neuritis when steroids are used in low concentration in peripheral nerve blocks. steroids have powerful anti-inflammatory as well as analgesic properties. perineural injection of steroids is reported to influence postoperative analgesia. they relieve pain by reducing inflammation, and blocking transmission of nociceptive c-fibres and by suppressing ectopic neural discharge. the addition of 5 mg of dexamethasone to 10 ml of 0.5% levobupivacaine in interscalene brachial plexus block showed improvement of postoperative analgesia for arthroscopic shoulder operation without any specific complications. the objective of this study is to compare the effects of combining of dexamethasone and bupivacaine versus bupivacaine alone in combined femoral and sciatic nerve block in patients undergoing lower limb vascular surgeries. the effects will be studied in terms of: * onset of sensory blockade and motor blockade * duration of analgesia / first request for analgesic * duration of motor blockade


Eligibility criteria:
inclusion criteria: * age ranging from 18 to 70 years * american society of anesthesiologists (asa) physical status i, ii and iii * patients scheduled for lower limb vascular surgeries exclusion criteria: * patient refusal for the procedure * any bleeding disorder or patients on anticoagulant therapy * neurological deficits involving lumbar or sacral plexuses * patients with allergy to local anaesthetics * local infection at the injection site * patients on any sedative or antipsychotic drugs * body mass index \> 35

Keywords: regional anesthesia dexamethasone bupivacaine femoral sciatic
congenital heart disease genetic network study (chd genes)

Conditions: Congenital Heart Defects

Summary: congenital heart defects (chd) are the most common major human birth malformation, affecting \~8 per 1,000 live births. chd are associated with significant morbidity and mortality, and are second only to infectious diseases in contributing to the infant mortality rate. current understanding of the etiology of pediatric cardiovascular disorders is limited. the congenital heart disease genetic network study (chd genes) is a multi-center, prospective observational cohort study. participants will be recruited from the pediatric cardiac genomics consortium's (pcgc) centers of the nhlbi-sponsored bench to bassinet (b2b) program. biological specimens will be obtained for genetic analyses, and phenotype data will be collected by interview and from medical records. state-of-the-art genomic technologies will be used to identify common genetic causes of chd and genetic modifiers of clinical outcome. to accomplish this, the pcgc will develop and maintain a biorepository of specimens (dna) and genetic data, along with detailed, phenotypic and clinical outcomes data in order to investigate relationships between genetic factors and phenotypic and clinical outcomes in congenital heart disease.


Eligibility criteria:
inclusion criteria: • signed consent form exclusion criteria: * isolated patent foramen ovale * isolated prematurity-associated patent ductus arteriosus
apathy in parkinson disease: clinical, physiopathological and pharmacological study

Conditions: Apathy in Parkinson Disease

Summary: apathy has been reported to occur after subthalamic nucleus stimulation (stn-dbs), a treatment of motor complications in advanced parkinson's disease (pd). it is not known whether postoperative apathy is related to dopamine withdrawal or a side effect of stn dbs. the researchers investigated potential predictors of apathy, and the effect of dopamine agonist treatment.


Eligibility criteria:
inclusion criteria: * parkinson disease exclusion criteria: * mattis scale \< 130 * beck scale \> 20

Keywords: apathy parkinson agonist dopaminergic
non-surgical periodontal therapy effects metabolic control in diabetics

Conditions: Metabolic Control

Summary: the purpose of this study is to determine whether nonsurgical periodontal therapy is effective in the metabolic control of patients with type ii diabetes mellitus.

type 2 diabetes mellitus (dm2), the most common type of diabetes, is characterized by hyperglycemia, hyperlipidemia, and associated complications. the classic major complications of diabetes are microangiopathy, nephropathy, neuropathy, macrovascular disease, delayed wound healing, and periodontitis. there is an interacting, complex relationship between diabetes and periodontitis.many studies have shown a greater incidence and a greater severity of periodontitis in diabetic patients.meanwhile, a number of studies have suggested that periodontitis may actually be a risk factor for diabetic complications as well. this study is performed to investigate the effects of non-surgical periodontal therapy on metabolic control in dm2 patients.

Eligibility criteria:
inclusion criteria: (1) mild to moderate periodontitis according to the criteria of the american academy of periodontology (32); (2) diagnosis of dm2 with glycated hemoglobin (hba1c) values over 7%; (3) no major diabetic complications; (4) blood sugar controlled with glybenclamide and metformin, without insulin administration; and (5) no systemic antibiotic administration or periodontal treatment within the last 6 months. exclusion criteria: (1) presence of systemic diseases other than dm2 that may influence the course of periodontal disease; (2) intake of immunosuppressive drugs, steroids, hydantoin, or non-steroidal anti-inflammatory drugs; (3) tobacco use; (4) pregnancy or intention to become pregnant during the study period; (5) fixed orthodontic appliances; and (5) refusal or inability to give informed consent

Keywords: metabolic control fasting plasma glucose glycated hemoglobin
recurrence rate of mini-slet vs. limbal-conjunctival autograft in primary pterygium excision

Conditions: Pterygium of Conjunctiva and Cornea

Summary: to study the efficacy and safety of amniotic membrane transplantation as an adjunctive therapy after surgical excision of primary pterygium and compare the clinical outcomes with conjunctival autograft

prospective randomized blind clinical trial sixty-four eyes of 64 patients with primary nasal pterygium have been operated by two surgeons (e. g-h, a. n-c). all patients are randomized to undergo mini-slet or limbal-conjunctival autograft transplantation as an adjuvant therapy after pterygium excision. four eyes were treated with mini-slet(group 1), and 26 eyes have been operated with conjunctival autograft (group 2). patients will be followed up at 1 day, 1 week, 1, 3, 6, 9 and 12 months postoperation. the main outcome measurement was a recurrence rate after surgery.

Eligibility criteria:
inclusion criteria: * patients with primary nasal pterygium \> 2mm exclusion criteria: * pregnant * previous ocular surgery

Keywords: crosslinking